Holen Sie sich die Stockscreener-App
4.73
3.86%
-0.19
Handel nachbörslich:
4.73
Schlusskurs vom Vortag:
$4.92
Offen:
$5
24-Stunden-Volumen:
1.81M
Relative Volume:
0.75
Marktkapitalisierung:
$513.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-240.91M
KGV:
-2.1045
EPS:
-2.2476
Netto-Cashflow:
$-202.83M
1W Leistung:
+7.26%
1M Leistung:
+44.65%
6M Leistung:
+49.68%
1J Leistung:
-44.35%
1-Tages-Spanne:
$4.625
$5.1199
1-Wochen-Bereich:
$4.39
$5.45
52-Wochen-Spanne:
$2.19
$8.89
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
4.73 | 534.16M | 0 | -240.91M | -202.83M | -2.2476 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-08-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-30 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Herabstufung | Needham | Buy → Hold |
| 2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-30 | Eingeleitet | Wedbush | Outperform |
| 2024-12-18 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Insider Buy: Is Rocket Pharmaceuticals Inc part of any ETF2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Enters New Sales Agreement with Cantor Fitzgerald, Terminates Prior Equity Offering Arrangement - Minichart
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.8%Should You Sell? - MarketBeat
Rocket Pharmaceuticals Launches New $100M At-The-Market Program - TipRanks
Rocket Pharmaceuticals enters $100 million at-the-market offering agreement - Investing.com
Rocket Pharmaceuticals (RCKT) Launches $100 Million Stock Offeri - GuruFocus
Rocket Pharmaceuticals Launches $100 Million ATM Offering With Cantor Fitzgerald - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co. - Bitget
Form 424B5 ROCKET PHARMACEUTICALS, - StreetInsider
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4%What's Next? - MarketBeat
UniQure leads genetic medicine biotech rally after news of Prasad’s exit - BioPharma Dive
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at Wall Street Zen - MarketBeat
Short Covering: Is Rocket Pharmaceuticals Inc Equity Warrant attractive for institutional investorsDollar Strength & Low Drawdown Investment Ideas - baoquankhu1.vn
Weekly Recap: Is Rocket Pharmaceuticals Inc showing insider buyingQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Rocket gene therapy among at least 7 PDUFA dates at FDA in March - BioCentury
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances - Yahoo! Finance Canada
Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital - Stock Titan
Goldman Sachs Maintains 'Sell' Rating on RCKT, Raises Price Targ - GuruFocus
The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating - TipRanks
Brokers Set Expectations for RCKT FY2026 Earnings - MarketBeat
Chart Watch: Is Rocket Pharmaceuticals Inc showing insider buying2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Lifesci Capital Upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Strong-Buy - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - The Globe and Mail
Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring A 71% Upside Potential - DirectorsTalk Interviews
Rocket Pharmaceuticals Q4 2025 Financial Report & Annual ResultsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 14.3% Following Earnings Beat - MarketBeat
Cantor Fitzgerald Raises Rocket Pharmaceuticals (RCKT) Price Tar - GuruFocus
Cantor Fitzgerald Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Rocket Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rocket Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Rocket Pharmaceuticals' (RCKT) Financial Position at Year-End - GuruFocus
[8-K] ROCKET PHARMACEUTICALS, INC. Reports Material Event | RCKT SEC FilingForm 8-K - Stock Titan
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress - The Joplin Globe
Rocket Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - The Joplin Globe
Rocket Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by Monaco Asset Management SAM - MarketBeat
Aug Shorts: What are analysts price targets for Rocket Pharmaceuticals Inc2025 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Is Rocket Pharmaceuticals Inc. Equity Warrant stock good for income investors2025 Trade Ideas & Safe Capital Growth Stock Tips - mfd.ru
Tax-related stock sale by Rocket Pharma (RCKT) CEO Gaurav Shah - Stock Titan
How Rocket Pharmaceuticals Inc. Equity Warrant stock performs in rising dollar environmentTrade Exit Report & Daily Profit Maximizing Trade Tips - mfd.ru
Analysts Recommend Rocket Pharmaceuticals as a Top Buy - Intellectia AI
Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery - Finviz
Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,253 Shares - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Insider John Militello Sells 3,726 Shares - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) CEO Sells $40,643.49 in Stock - MarketBeat
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shah Gaurav | CEO |
Feb 18 '26 |
Sale |
3.34 |
5,990 |
19,995 |
1,046,055 |
| Wilson Martin | General Counsel |
Feb 18 '26 |
Sale |
3.34 |
1,376 |
4,593 |
682,000 |
| Wilson Martin | General Counsel |
Feb 13 '26 |
Sale |
3.31 |
12,253 |
40,582 |
683,376 |
| Militello John | See Remarks |
Feb 13 '26 |
Sale |
3.31 |
3,726 |
12,341 |
92,176 |
| Shah Gaurav | CEO |
Feb 13 '26 |
Sale |
3.31 |
12,279 |
40,668 |
1,052,045 |
0.48%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):